Allurion Technologies announced a new partnership with Argentine obesity‑care provider Bionut and pharmacy partner Farmastar to provide patients with discounted tirzepatide (Mounjaro) for use alongside the Allurion Smart Capsule. The deal gives Allurion a direct distribution channel in Argentina and positions the company to bundle its swallowable balloon with a low‑dose GLP‑1 therapy.
The partnership is a key step in Allurion’s pivot to a drug‑device platform. By pairing the Smart Capsule with Mounjaro, the company aims to address the adherence and muscle‑mass loss issues that limit GLP‑1 monotherapy, while creating a higher‑margin revenue stream. The Argentine rollout also serves as a testbed for the combination therapy model that Allurion plans to expand globally.
Allurion’s financial performance has been under pressure, with Q3 2025 revenue falling 50% YoY to $2.7 million and operating losses narrowing to $9.6 million. The company has maintained a full‑year 2025 revenue guidance of roughly $3 million and is targeting a 50% reduction in operating expenses versus 2024. The partnership is intended to accelerate revenue growth and improve gross margins, which were 49% in Q3 2025 compared to 58% in the prior year, by leveraging the high‑margin drug component.
CEO Shantanu Gaur said, “GLP‑1s alone are not the answer because of side effects, poor adherence, and loss of muscle mass. By combining the Smart Capsule with low‑dose tirzepatide, we can deliver sustained weight loss while preserving lean body mass.” The statement underscores the company’s focus on a next‑generation treatment that could differentiate it in a crowded obesity‑drug market.
The Argentine partnership expands Allurion’s commercial footprint and supports its broader strategy to roll out the combination therapy worldwide. While the deal offers a new revenue channel, the company still faces challenges such as regulatory approval for the Smart Capsule in the U.S., ongoing operating losses, and a negative equity position. Nonetheless, the partnership signals Allurion’s commitment to a drug‑device model that could reshape obesity treatment if the combination proves clinically and commercially successful.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.